Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib

Authors
Publication date
1 January 2022
Publisher
'Springer Science and Business Media LLC'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      King's Research Portal

      redirect
      oaioai:kclpure.kcl.ac.uk:publicat...
      Last time updated on 28/09/2023

      IRIS Università Politecnica delle Marche

      redirect
      oaioai:iris.univpm.it:11566/30792...
      Last time updated on 26/11/2022